دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Fractional flow reserve or 3D-quantitative-coronary-angiography based vessel-FFR guided revascularization. Rationale and study design of the prospective randomized fast III trial
Alessandra Scoccia, MD, 1 , Robert A. Byrne, MB, BCh, PhD, FESC, 2,3 , Adrian P. Banning, MD, 4 , Ulf Landmesser, MD, 5 , Eric Van Belle, MD, PhD, 6,7 , Ignacio J. Amat-Santos, MD, 8 , Manel Sabaté, MD, 9 , Jan G.P. Tijssen, PhD, 10 , Ernest Spitzer, MD, 1,11 , and Joost Daemen, MD, PhD, FESC 1 Rotterdam; The Netherlands, Lille; France, Lille; France, Valladolid; Spain, Rotterdam; The Netherlands, Rotterdam; The Netherlands
doi : 10.1016/j.ahj.2023.02.003
Volume 260, June 2023, Pages 1-8
Rationale and design of the RESTORE trial: A multicenter, randomized, double-blinded, parallel-group, placebo-controlled trial to evaluate the effect of Shenfu injection on myocardial injury in STEMI patients after primary PCI
Xiao Wang, MD a , Ruifeng Guo, MD, PhD a , Yingying Guo, MD a , Qian Guo, MD a , Yan Yan, MD a , Wei Gong, MD, PhD a , Wen Zheng, MD, PhD a , Hui Wang, MD b , Lei Xu, MD b , Hui Ai, MD a , Bin Que, MD a , Xiaoyan Yan, MD c , Xinliang Ma, MD, PhD d , and Shaoping Nie, MD, PhD a Beijing, China; Beijing, China; Philadelphia, PA;
doi : 10.1016/j.ahj.2023.02.005
Volume 260, June 2023, Pages 9-17
The mortality following ST-segment elevation myocardial infarction (STEMI) remains substantial in the reperfusion era. Shenfu injection, as a traditional Chinese herbal formula, can alleviate ischemia-reperfusion injury through multiple pharmacologic effects. However, no robust data are available regarding the role of Shenfu injection in reducing infarct size for patients with STEMI undergoing primary percutaneous coronary intervention (PPCI).
Rationale and study design of the GOREISAN for heart failure (GOREISAN-HF) trial: A randomized clinical trial
Hidenori Yaku, MD a,b , Takao Kato, MD a , Takeshi Morimoto, MD MPH c , Kazuhisa Kaneda, MD a , Ryusuke Nishikawa, MD a , Takeshi Kitai, MD d , Yasutaka Inuzuka, MD e , Yodo Tamaki, MD f , Taketoshi Yamazaki, MD g , Jun Kitamura, MD h , Hirotaka Ezaki, MD i , Kazuya Nagao, MD j , Hiromi Yamamoto, MD k , Akihiro Isotani, MD l , Arita Takeshi, MD m , Chisato Izumi, MD d , Yukihito Sato, MD n , Yoshihisa Nakagawa, MD o , Satoaki Matoba, MD p , Yasushi Sakata, MD q , Koichiro Kuwahara, MD r , and Takeshi Kimura, MD a , for the GOREISAN-HF trial Investigators Kyoto, Japan; Chicago, IL; Nishinomiya, Japan; Osaka, Japan; Moriyama, Japan; Nara, Japan; Kobe, Japan; Tokorozawa, Japan; Tokorozawa, Japan; Osaka, Japan; Kurashiki, Japan; Fukuoka Wajiro, Japan; Amagasaki, Japan; Otsu, Japan; Suita, Japan; Nagano, Japan
doi : 10.1016/j.ahj.2023.02.013
Volume 260, June 2023, Pages 18-25
The decongestion strategy using loop diuretics is essential for improving signs and symptoms of heart failure (HF). However, chronic use of loop diuretics in HF has been linked to worsening renal function and adverse clinical outcomes in a dose-dependent manner.
Prospective randomized comparison between upgraded ‘2C3L’ vs. PVI approach for catheter ablation of persistent atrial fibrillation: PROMPT-AF trial design
Xiao-Xia Liu, MD a , Qiang Liu, MD b , Yi-Wei Lai, MD a , Qi Guo, MD a , Rong Bai, MD a,c , De-Yong Long, MD a , Rong-Hui Yu, MD a , Ri-Bo Tang, MD a , Nian Liu, MD a , Chen-Xi Jiang, MD a , Wei Wang, MD a , Xue-Yuan Guo, MD a , Song-Nan Li, MD a , Xin Zhao, MD a , Song Zuo, MD a , Chang-Yi Li, MD a , Shang-Ming Song, MD d , Shuang-Lun Xie, MD e , Wei-Li Ge, MD f , Jian-Gang Zou, MD g , Xiao-Feng Hou, MD g , Ke Chen, MD h , Jin-Lin Zhang, MD i , He-Sheng Hu, MD j , Xin-Hua Wang, MD k , Zhao-Jun Wang, MD l , Xin Du, MD a,m,n,o , Chen-Yang Jiang, MD b , Cai-Hua Sang, MD a , Jian-Zeng Dong, MD a,p , and Chang-Sheng Ma, MD a Beijing, China;
doi : 10.1016/j.ahj.2023.01.019
Volume 260, June 2023, Pages 34-43
Nationwide Utilization of Danish Government Electronic letter system for increasing inFLUenza vaccine uptake (NUDGE-FLU): Study protocol for a nationwide randomized implementation trial
Niklas Dyrby Johansen, MD a,b , Muthiah Vaduganathan, MD, MPH c,d , Ankeet S. Bhatt, MD, MBA c,d,e , Simin Gharib Lee, MD, MBA c,d , Daniel Modin, MB a,b , Brian L. Claggett, PhD c , Erica L. Dueger, DVM, PhD f , Sandrine Samson, PhD f , Matthew M. Loiacono, PhD g , Lars K?ber, MD, DMSc h,i , Scott D. Solomon, MD c , Pradeesh Sivapalan, MD, PhD j , Jens Ulrik St?hr Jensen, MD, PhD j , Palle Valentiner-Branth, MD, PhD k , Tyra Grove Krause, MD, PhD k , and Tor Biering-S?rensen, MD, MSc, MPH, PhD a,b
doi : 10.1016/j.ahj.2023.02.009
Volume 260, June 2023, Pages 58-71
Annual influenza vaccination is widely recommended in older adults and other high-risk groups including patients with cardiovascular disease. The real-world effectiveness of influenza vaccination is limited by suboptimal uptake and effective strategies for increasing vaccination rates are therefore needed.
A randomized controlled trial of gamification, financial incentives, or both to increase physical activity among patients with elevated risk for cardiovascular disease: rationale and design of the be active study
Alexander C. Fanaroff, MD, MHS a,b,c,d,e , Mitesh S. Patel, MD, MBA f , Neel Chokshi, MD, MBA a,d,e , Samantha Coratti, BS c , David Farraday, BA c , Laurie Norton, MA, MBE c,g , Charles Rareshide, MS c , Jingsan Zhu, MS, MBA a,c,g , Julia E. Szymczak, PhD h , Louise B. Russell, PhD c,d,g , Dylan S. Small, PhD d,i , and Kevin G.M. Volpp, MD, PhD
doi : 10.1016/j.ahj.2023.02.014
Volume 260, June 2023, Pages 82-89
The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score
Christopher S. Almond a , Lynn A. Sleeper, ScD b , Joseph W. Rossano, MD MS c , Matthew J. Bock, MD d , Elfriede Pahl, MD e , Scott Auerbach, MD f , Ashwin Lal, MD g , Seth A. Hollander, MD a , Shelley D. Miyamoto, MD f , Chesney Castleberry, MD h , Joanne Lee, PharmD a , Lynsey M. Barkoff, NP a , Selena Gonzales, MPH a , Gloria Klein, MS, RD b , and Kevin P. Daly, MD
doi : 10.1016/j.ahj.2023.02.002
Volume 260, June 2023, Pages 100-112
Currently there are no immunosuppression regimens FDA-approved to prevent rejection in pediatric heart transplantation (HT). In recent years, everolimus (EVL) has emerged as a potential alternative to standard tacrolimus (TAC) as the primary immunosuppressant to prevent rejection that may also reduce the risk of cardiac allograft vasculopathy (CAV), chronic kidney disease (CKD) and cytomegalovirus (CMV) infection.
Risk factor associations with individual myocardial infarction subtypes and acute non-ischemic myocardial injury in the Multi-Ethnic Study of Atherosclerosis (MESA): Design and rationale
Andrew P. DeFilippis, MD, MSc a,†, Karita C.F. Lidani, MD, MSc, PhD a,†, Yunbi Nam, MSc b , Patrick J. Trainor, PhD, MS, MA c , W Craig Johnson, MSc b , Susan R. Heckbert, MD, PhD d , Robyn L. McClelland, PhD b , Michael J. Blaha, MD, MPH e,‡ , and Khurram Nasir, MD, MPH f,‡ Nashville, TN; Seattle, WA; Las Cruces, NM; Baltimore, MD; Houston, TX
doi : 10.1016/j.ahj.2023.02.012
Volume 260, June 2023, Pages 151-173
Despite different prevalence, pathobiology, and prognosis between etiologically distinct myocardial infarction (MI) subtypes, prospective study of risk factor for MI in large NHLBI-sponsored cardiovascular cohorts is limited to acute MI as a singular entity. Therefore, we sought to utilize the Multi-Ethnic Study of Atherosclerosis (MESA), a large prospective primary prevention cardiovascular study, to define the incidence and risk factor profile of individual myocardial injury subtypes.
Perioperative bleeding and outcomes after noncardiac surgery
Nathaniel R. Smilowitz, MD, MS a,b , Kurt Ruetzler, MD, PhD c , and Jeffrey S. Berger, MD, MS a,d New York, NY; New York, NY; Cleveland, OH; New York, NY;
doi : 10.1016/j.ahj.2023.02.008
Volume 260, June 2023, Pages 26-33
Perioperative bleeding is a common and potentially life-threatening complication after surgery. We sought to identify the frequency, patient characteristics, causes, and outcomes of perioperative bleeding in patients undergoing noncardiac surgery.
Variation in resource utilization and mortality among patients with varying MR type and severity
Jennifer A. Rymer, MD, MBA, MHS a,b , Jie-Lena Sun, MS b , Karen Chiswell, PhD b , David Cohen, MD c,d , Kate Vilain, MPH e , Andrew Wang, MD b , Zainab Samad, MD f , Tracy Y. Wang, MD, MHS, MS a,b , and Pamela S. Douglas, MD b Durham, NC; Durham, NC; New York, NY; Roslyn, NY; Kansas City, NO; Karachi, Pakistan;
doi : 10.1016/j.ahj.2023.01.005
Volume 260, June 2023, Pages 44-57
Limited data exists regarding the relationships between resource use and outcomes in patients with mitral regurgitation (MR). We examined resource utilization and outcomes across MR type and severity.
External validation of bleeding risk models for the prediction of long-term bleeding risk in patients with established cardiovascular disease
Maria C. Castelijns, MD a , Steven H.J. Hageman, PhD a , Martin Teraa, PhD b , Manon G. van der Meer, PhD c , Jan Westerink, PhD a,d , Francesco Costa, PhD e , Jurriën M. ten Berg, PhD f,g , and Frank L.J. Visseren, PhD
doi : 10.1016/j.ahj.2023.02.011
Volume 260, June 2023, Pages 72-81
The long-term predictive performance of existing bleeding risk models in patients with various manifestations of cardiovascular disease (CVD) is not well known. This study aims to assess and compare the performance of relevant existing bleeding risk models in estimating the long-term risk of major bleeding in a cohort of patients with established CVD.
The effect of tablet computer-based telemonitoring added to an established telephone disease management program on heart failure hospitalizations: The Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) III Randomized Controlled Trial
Jenica N. Upshaw, MD, MS a , Susan Parker, RN b , Douglas Gregory, PhD c , Benjamin Koethe, MS d , Amanda R. Vest, MBBS, MPH a , Ayan R. Patel, MD a , Michael S. Kiernan, MD a , David DeNofrio, MD a , Eric Davidson, MD e , Sharanya Mohanty, MD a , Patrick Arpin, DO a , Nicole Strauss, MPH a , Crystal Sommer, MS a , Linda Brandon, RN b , Rita Butler, MD a , Henry Dwaah, BA f , Hilary Nadeau, RN b , Michael Cantor, MD, JD
doi : 10.1016/j.ahj.2023.02.007
Volume 260, June 2023, Pages 90-99
Mobile health applications are becoming increasingly common. Prior work has demonstrated reduced heart failure (HF) hospitalizations with HF disease management programs; however, few of these programs have used tablet computer-based technology.
Postoperative pericardial effusion, pericardiotomy, and atrial fibrillation: An explanatory analysis of the PALACS trial
Lisa Q. Rong, MD, MS a , Antonino Di Franco, MD b , Mohamed Rahouma, MD b , Arnaldo Dimagli, MD b , June Chan, MBBS a , Alexandra J. Lopes, BA a , Jiwon Kim, MD c , Tommaso Sanna, MD d,e , Richard B. Devereux, MD c , Victoria Delgado, MD, PhD f,g , Jonathan W. Weinsaft, MD c , Filippo Crea, MD d,e , John H. Alexander, MD h , Marc Gillinov, MD i , John Michael DiMaio j , Kane O. Pryor, MD a , Leonard Girardi, MD b , and Mario Gaudino, MD, PhD
doi : 10.1016/j.ahj.2023.03.001
Volume 260, June 2023, Pages 113-123
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method
Che Ngufor, PhD a,b , Xiaoxi Yao, PhD a,c , Jonathan W. Inselman, MS a,c , Joseph S. Ross, MD, MHS d,e , Sanket S. Dhruva, MD, MHS f,g , David J. Graham, MD, MPH h , Joo-Yeon Lee, PhD i , Konstantinos C. Siontis, MD j , Nihar R. Desai, MD, MPH e , Eric Polley, PhD l , Nilay D. Shah, PhD k , and Peter A. Noseworthy, MD
doi : 10.1016/j.ahj.2023.02.015
Volume 260, June 2023, Pages 124-140
P-wave terminal force in lead V1 and outcomes in patients with persistent atrial fibrillation undergoing catheter ablation
Yuya Sudo, MD a , Takeshi Morimoto, MD, PhD, MPH b , Ryu Tsushima, MD a , Masahiro Sogo, MD a , Masatomo Ozaki, MD a , Masahiko Takahashi, MD a , and Keisuke Okawa, MD, PhD
doi : 10.1016/j.ahj.2023.03.006
Volume 260, June 2023, Pages 141-150
